Key Investor Signals
Signed LOIs with industry companies
Aortex signed letters of intent with companies in the sector before bringing its product to market.
Patent application filed, with novelty confirmed
Aortex filed a patent application covering its stent graft manufacturing technology in March 2025. The confirmed its novelty.
Won five startup and innovation competitions
Aortex won the 2026 in the Start category, after the competition drew more than 80 entries. It also won Gründergeist 2025, Venture Day, The Ventures Best Product, and START Paris.
Other Positive Signals
- Completed a working prototype of its patient-specific, low-profile stent graft.
- Selected for Hamburg's public innovation funding programme.
- CTO Maximilian Dunker previously managed multimillion-euro global projects from prototype and validation through serial production.
- Selected for the acceleration portfolio.
- Joined the later-stage track of Batch VIII.
Team
Henry Stehle
CEO and co-founder
- Served as CFO of BioInterio, which developed fibre-based composite materials at RWTH Aachen's textile technology institute.
- Spent three years in strategy consulting at Accenture before founding Aortex.
- Holds a master's in management and engineering in production systems from RWTH Aachen University.
- Received the NRW Gründerstipendium, North Rhine-Westphalia's scholarship for company founders.
Maximilian Dunker
CTO and co-founder
- Managed multimillion-euro global projects at Vibracoustic from prototype and validation through serial production.
- Designed a 3D-printed cylinder head that was 30% lighter and reduced cooling pressure loss by 75%.
- Built an automated BMW design tool that generated welding-gun geometry after maintenance.
- Holds a master's in mechanical engineering from RWTH Aachen University.
Product
Aortex is developing patient-specific stent grafts for . Its initial target is patients whose access vessels are too small or whose anatomy is too complex for conventional devices, leaving open surgery as their principal alternative.
Up to 20% smaller delivery catheters
Aortex makes the membrane half as thick as current models, enabling delivery catheters up to 20% smaller and extending treatment to patients with narrower arteries.
Patient-specific implants made in days
Each implant is shaped from the patient's 3D CT data and produced through an automated, single-step process. This reduces the production time for a custom stent graft from months to days—an important difference when an aneurysm is at risk of rupture.
Designed for longer durability
The thinner membrane is designed to last longer than conventional alternatives and reduce the need for repeat procedures as implants age.
Market Overview
Aortic aneurysms can rupture without warning and cause fatal internal bleeding. Around 15,000 people die from ruptured aortic aneurysms each year in the United States. is already an established treatment, with hospitals routinely purchasing stent graft systems from companies including Medtronic, W. L. Gore and Cook Medical.
The remaining gap is anatomical eligibility. Smaller access vessels and more complex aortic anatomy can prevent patients, particularly women, from receiving conventional endovascular repair. Meanwhile, the global market is forecast to grow from $5.0 billion in 2025 to $12.9 billion in 2033, creating a validated market for lower-profile and patient-specific devices.
Around 15,000 people die from ruptured aortic aneurysms each year in the United States.
A pooled analysis found only 34% of women anatomically suitable for conventional endovascular repair, compared with 54% of men.
Aortic stent grafts accounted for 80.1% of aortic aneurysm product revenue in 2025.
The global aortic aneurysm market is projected to grow from $5.0 billion in 2025 to $12.9 billion in 2033.
Comparable Outcomes
JOTEC
JOTEC developed endovascular and surgical grafts for thoracic and abdominal aortic disease, manufactured in Germany and sold through its own teams across Europe and Latin America. JOTEC established the value of a German-engineered stent graft business to a strategic acquirer. acquired JOTEC for $225M in December 2017.
Embody
Embody developed collagen-based implants for tendon, rotator cuff and other difficult soft-tissue injuries. Its value sat in the implantable material itself rather than in the surgical instruments around it. acquired Embody for up to $275M in February 2023.
Kerecis
Kerecis developed fish-skin grafts for chronic, diabetic and surgical wounds. acquired the company in August 2023 for up to $1.3B, demonstrating strategic buyer interest in advanced wound-care businesses.
Have a question about Aortex?
Ask DealBio. We may research the answer or share selected questions with the company.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.